Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.4252W HIGH $7.95
Volume
543.77 K
Value Traded
2.28 M
Short % Float
7.46%
Days to Cover
9.9
-2.8%Week
-20.33%1 Month
-24.77%3 Month
-51.01%6 Month
-53.96%5 Year
-88.38%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
193.54 M
EPS (TTM)
0.20
P/E Ratio
12.02
Ent. Value
126.80 M
Total Shares
79.69 M
Float Shares
51.96 M
Insiders
34.33%
Institutions
41.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NAGE Catalyst Timeline
Dated clinical, regulatory and corporate events for Niagen Bioscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Niagen Bioscience, Inc.
301Total events
5Upcoming
65Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Product LaunchNiagenPlusPost-Market
Launch of Niagen At-Home Injection Kit with ready-to-inject liquid formulation via Niagen Plus telehealth
▲Partnership / LicenseNiagenPlusCorporate
Restore Hyper Wellness and Niagen Bioscience partner to promote Longevity Month and Niagen plans
▲Partnership / LicenseCorporate
Restore Hyper Wellness and Niagen Bioscience partner for Longevity Month campaign
▲Timing GuidanceNiagenPlusPresentation
Start-Up Agreement with Mass General Brigham to plan largest Niagen healthy aging clinical trial
healthy agingsource ↗
▲Preclinical PoCnicotinamide ribosidePreclinical
Preclinical study published in Nature Communications showing CD38 drives age-related NAD+ decline and NR restores NAD+ and improves pregnancy outcomes
age-related NAD+ decline and pregnancy outcomessource ↗
●R&D DayPresentation
Niagen Bioscience senior management to present at 17th Annual Midwest IDEAS Investor Conference
●R&D DayPresentation
Niagen Bioscience to participate in Canaccord Genuity 46th Annual Growth Conference
●Quarterly UpdateCorporate
Niagen Bioscience to report Q2 2026 financial results and hold conference call
▲Partnership / LicenseNB4168Corporate
Selected Evotec as CRO to support preclinical development of NB4168
Ataxia Telangiectasiasource ↗
▲PublicationNiagenPlusPresentation
Publication of analysis in Aging Cell showing Niagen supplementation reduced muscle epigenetic age acceleration
biological agingsource ↗
▲Rare Pediatric DiseaseNB4168Designation
FDA Rare Pediatric Disease Designation for NB4168 for A-T
Ataxia Telangiectasia (A-T)source ↗
▲EU Orphan DesignationNB4168Ex-US Regulatory
EMA Orphan Medicinal Product Designation for NB4168 for A-T
Ataxia Telangiectasia (A-T)source ↗
▲Program DiscontinuationCorporate
Launch of pharmaceutical program for accelerated aging and rare genetic diseases
accelerated aging and rare genetic diseasessource ↗
▲Trial InitiationTrial
Launch of first drug candidate of NAD Pharmaceuticals Corp.
accelerated aging and rare genetic diseasessource ↗
◆Timing GuidanceNB4168Presentation
Preclinical and IND-enabling studies for NB4168 anticipated to begin in Q3 2026
Ataxia-Telangiectasia (A-T)source ↗
◆Oral PresentationPresentation
Presentation at 16th Annual East Coast IDEAS Investor Conference
▲Product LaunchNiagenPlusPost-Market
Launch of Niagen Plus Telehealth Platform and at-home injection kit
▲Product LaunchNiagenPlusPost-Market
Launched clinician-directed telehealth platform under Niagen Plus
▲Partnership / LicenseNiagenPlusCorporate
Partnership with Olympia Pharmaceuticals for compounding and distribution of Niagen Plus
▲Manufacturing MilestoneNiagenPlusCMC / Inspection
USP publishes first-ever monograph for Nicotinamide Riboside Chloride (NRCl), the patented form in Niagen
▲Manufacturing Milestonenicotinamide riboside chlorideCMC / Inspection
First USP monograph for nicotinamide riboside chloride established
▲Manufacturing MilestoneNiagenPlusCMC / Inspection
First USP monograph for nicotinamide riboside chloride established
▲Rare Pediatric DiseaseNB4168Designation
NB4168 received FDA Rare Pediatric Disease designation for A-T
Ataxia-Telangiectasia (A-T)source ↗
▲EU Orphan DesignationNB4168Ex-US Regulatory
NB4168 received EMA Orphan Medicinal Product Designation for A-T
Ataxia-Telangiectasia (A-T)source ↗
▲Partnership / LicenseCorporate
First cruise ship clinic partnership with OneSpaWorld to offer Niagen IV at over 80 Medi-Spa clinics onboard cruise ships
▲Patent GrantedNiagenPlusIP / Competition
Newly granted patent covering methods of use of Niagen (patented NR) and derivatives in IV and injectable formulations
◆Oral PresentationPresentation
Niagen Bioscience is premiere sponsor of inaugural NAD for Health conference
▲PreprintNiagenPlusPresentation
Preprint on single-use topical Niagen skin benefits published to Preprints.org
skin moisture and smoothnesssource ↗
▲ATM ProgramCorporate
Board authorized increase of share repurchase program from $10M to $20M
▲Enrollment MilestoneNiagenPlusTrial
External research program surpasses 300 material transfer agreements
▲Partnership / LicenseNiagenPlusCorporate
Expanded Niagen Plus clinical channel with first cruise ship clinic partnership
▲Product LaunchPost-Market
Entered skincare category with launch of Niagen's Nanocloud topical product
▲Product LaunchNiagenPlusPost-Market
Entered skincare category with launch of Niagen's Nanocloud
▲Partnership / LicenseCorporate
Expanded Niagen Plus clinical channel with first cruise ship clinic partnership
▲Product LaunchNanocloudPost-Market
Entered skincare category with Niagen's Nanocloud topical product
▲AcquisitionCorporate
Completed divestiture of Analytical Reference Standards and Services segment to LGC Standards
▲Partnership / LicenseCorporate
Partnership with Truemed to enable HSA/FSA purchases of Tru Niagen
▲PreprintNiagenPlusPresentation
Two open-label pilot studies of sub-q and IM Niagen injections published as preprints on medRxiv
fatiguesource ↗
▲Partnership / LicenseCorporate
Acquired core NR patent portfolio from Queen's University Belfast
Past FDA Catalysts and PDUFA Decisions
How NAGE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 63%
Micro Cap(rank 414 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NiagenPlus Small moleculeNCT07251608 | Fatigue | Phase 1 | RECRUITING | 40 | Feb 15, 2026 | ||||||
| Niagen, Niagen, Niagen UnknownCompletedNCT02191462 | Undisclosed | Phase 1 | COMPLETED | 12 | Aug 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every NAGE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NIAGEN PriorityOrphan | 2015-02-11 | a single dose of NR resulted in statistically significant increases in the co-enzyme nicotinamide adenine dinucleotide (NAD+)Read More | ChromaDex's NIAGEN Nicotinamide Riboside Meets Primary Endpoint in First Human Clinical Study - Results Confirm That NR Increases the Mitochondrial Co-enzyme NAD+ and is Safe - - Full Study Results to be Peer Reviewed foRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Lopez Carlos LuisOfficer (SVP, General Counsel) | Grant/Award | 2,314 4,565 held | $2.71 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NAGE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NAGE for Q2 2026. | ||||
NAGE Institutional Ownership Trends
NAGE Short Interest
Shares sold short, counted twice a month.
7.46%
Short % of Float
of tradable shares sold short
3.9M
Shares Sold Short
-3.1% vs prior count
9.9 High
Days to Cover
trading days of normal volume to buy every short share back
393.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NAGE ranks across every disease it competes in
Competitive Position is a premium feature
See how NAGE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNAGE News
NAGE▼ -1.6%today
Niagen Bioscience Launches Niagen™ Plus Liquid At-Home Injections to Support Telehealth Expansion
Niagen Bioscience has launched the Niagen™ Plus Liquid At-Home Injection Kit, a prescription-only product aimed at supporting telehealth. This kit features the first ready-to-inject formulation of Niagen™, a patented nicotinamide riboside. The company emphasizes its commitment to the science of healthy aging through this innovative offering.
Read more →NAGENiagen Bioscience Makes Skincare a Permanent Tru Niagen® Category, Launching Dermatologist-Tested Niagen NanoCloud™ as a Core Tru Niagen® Product
Niagen Bioscience has launched Niagen NanoCloud, a dermatologist-tested skincare product, as part of its new Tru Niagen Skincare category. This innovative product utilizes a waterless, precision-dosed sachet technology to preserve its active ingredients until activation. The skincare market is projected to grow significantly, highlighting the potential for Niagen's entry into this sector.
Read more →NAGENiagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026
Niagen Bioscience, Inc. will hold a conference call on November 4, 2026, to discuss its third-quarter financial results for the period ending September 30, 2026. The company will release its financial results after market hours on the same day. The call will provide insights into the company's performance and future business updates.
Read more →NAGERestore Hyper Wellness® and Niagen Bioscience Team Up to Help Americans Age Better This October
Restore Hyper Wellness and Niagen Bioscience have declared October as 'Longevity Month' to promote the importance of healthspan over lifespan. They emphasize the need for energy, recovery, and resilience at any age. The initiative includes sharing signs of aging and practical advice for improving health through personalized therapies. Special promotions on Niagen plans are available throughout the month.
Read more →NAGEAndrew Shao, Ph.D., Senior Vice President of Global Regulatory and Scientific Affairs at Niagen Bioscience, Honored with the 2026 Annette Dickinson Trailblazer Award by Radicle Science and Council for Responsible Nutrition (CRN)
Andrew Shao, Ph.D., has been awarded the 2026 Annette Dickinson Trailblazer Award for his significant contributions to NAD+ research and the dietary supplement industry. The award, presented by Radicle Science and the Council for Responsible Nutrition, highlights Dr. Shao's commitment to scientific excellence and responsible innovation. His leadership and advocacy have positively impacted the industry, reflecting the legacy of Annette Dickinson.
Read more →NAGENiagen Bioscience to Present at LD Micro 20th Annual Main Event
Niagen Bioscience, Inc. will present at the 20th Annual LD Micro Main Event in Los Angeles from October 19 to 21, 2026. CEO Robert Fried is scheduled to present on October 21st, while CFO Ozan Pamir will be available for one-on-one meetings with investors. A replay of the presentation will be accessible on the company's Investor Relations website.
Read more →NAGE▼ -8.2%on this newsshared move
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.®” a New Campaign for its Niagen® Brand Featuring Legendary Surfer Kelly Slater
Niagen Bioscience has launched the 'Don't Get Old. Age Better.' campaign featuring Kelly Slater, emphasizing the importance of healthy aging supported by over 25 years of scientific research. The campaign highlights the benefits of Niagen, a patented NAD+ precursor, and includes endorsements from over 20 partners in various fields. The initiative aims to reshape perceptions of aging and promote proactive health choices.
Read more →NAGENiagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Niagen Bioscience has entered a Start-Up Agreement with Mass General Brigham to plan a large-scale, randomized, placebo-controlled clinical trial assessing the effects of Niagen (nicotinamide riboside) on healthy aging in adults aged 50 and older. This trial aims to evaluate various clinical outcomes and biomarkers associated with aging. The initiative seeks collaboration from other organizations to enhance the study's scientific rigor.
Read more →NAGENewly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
A preclinical study published in Nature Communications reveals that the CD38 enzyme significantly contributes to NAD+ depletion in placental tissue, particularly in older mothers. The study found that restoring NAD+ levels using nicotinamide riboside (NR) improved pregnancy outcomes in aged mice. This research highlights the potential for NR to counteract age-related reproductive challenges.
Read more →NAGENiagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Niagen Bioscience has engaged Red Sky Partners and Dr. Martin Hendrix to enhance its drug development efforts for NB4168, targeting rare genetic diseases and aging-related disorders. The advisors bring extensive experience in biopharmaceuticals, corporate strategy, and M&A. This strategic move aims to leverage their expertise to advance the company's growth and drug development initiatives.
Read more →NAGENiagen Bioscience to Present at Canaccord Genuity’s Well Summit
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced its participation in Canaccord Genuity's Well Summit from September 28 to 30, 2026. CEO Rob Fried and CFO Ozan Pamir will represent the company, with Fried speaking on a panel about aging. The event offers networking opportunities for leaders in the Consumer Health & Wellness sector.
Read more →NAGENiagen Bioscience to Present at Longevity Investors Conference
Niagen Bioscience, Inc. will present at the Longevity Investors Conference from September 14 to 17, 2026, in Gstaad, Switzerland. CEO Rob Fried will participate in a panel discussing the investment case for consumer health. The conference aims to connect institutional investors with leading scientists to discuss advancements in longevity research.
Read more →NAGENiagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Niagen Bioscience, Inc. will present at the Nasdaq X LD Micro Inaugural SF Summit on September 9, 2026. CFO Ozan Pamir will deliver a presentation and participate in breakout sessions for investor engagement. The event highlights Niagen's leadership in NAD+ science and its commitment to healthy aging.
Read more →NAGENiagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam’s Club
Niagen Bioscience, Inc. has announced the expansion of its Tru Niagen® supplement into nearly 300 GNC and Sam’s Club locations across 44 states. This move aims to reach a broader audience of health-conscious consumers. The supplement is recognized for its scientific backing and effectiveness in promoting healthy aging by boosting NAD+ levels.
Read more →NAGENiagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference
Niagen Bioscience, Inc. will present at the 17th Annual Midwest IDEAS Investor Conference on August 27, 2026. The event will take place at The InterContinental Chicago, providing a platform for the company to showcase its investment potential. Niagen is known for its expertise in NAD+ and healthy aging.
Read more →NAGENiagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence
Niagen Bioscience, Inc. has announced the launch of its popular NAD+ supplement, Tru Niagen®, on Walmart.com. This move aims to enhance consumer access to the product through a major digital retail platform. Tru Niagen is recognized as the leading healthy-aging supplement in the United States, marking a significant expansion for the company.
Read more →NAGE▼ -14.7%on this newsshared move
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Niagen Bioscience, Inc. reported its financial results for the second quarter of 2026, highlighting total net sales of $29.8 million, with a significant portion coming from its Tru Niagen® product. The company experienced a 23% increase in direct to consumer sales compared to the previous year, and achieved a gross margin of 64.8%. Net income for the quarter was reported at $1.0 million.
Read more →NAGENiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
Niagen Bioscience has partnered with Evotec to advance the preclinical development of NB4168. This collaboration aims to leverage Evotec's expertise in drug discovery and development. The initiative aligns with Niagen's focus on NAD+ and healthy aging, potentially leading to significant advancements in this area.
Read more →NAGENiagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
Niagen Bioscience, Inc. has announced the publication of a peer-reviewed analysis in Aging Cell, highlighting the positive effects of Niagen® (nicotinamide riboside) supplementation. The study indicates that this supplementation is associated with a reduction in muscle epigenetic age acceleration, as measured by the Muscle Epigenetic Age Test (MEAT) clock. This finding supports the potential of Niagen® in promoting healthy aging.
Read more →NAGENiagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
Niagen Bioscience, Inc. will be represented at Canaccord Genuity's 46th Annual Growth Conference. CEO Rob Fried and CFO Ozan Pamir will participate, with Fried scheduled for a fireside chat on August 11, 2026. This event emphasizes the company's commitment to healthy aging and NAD+ research.
Read more →About Niagen Bioscience, Inc.
Headquarters10900 WILSHIRE BLVD, LOS ANGELES, CA, 90024
BIOPHARMAWATCH ELITE PLUS
Trade the next NAGE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime